In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
Against 443 aerobic and anaerobic bacteria isolated from diabetic foot infections, ceftobiprole MICs (microg/ml) at which 90% of the isolates tested were inhibited were as follows: methicillin-resistant Staphylococcus aureus, 1; methicillin-susceptible S. aureus and Staphylococcus lugdunensis, 0.5; Anaerococcus prevotii, 0.125; Finegoldia magna, 0.5; Peptoniphilus asaccharolyticus, 1; Peptostreptococcus anaerobius, 4; Escherichia coli and Enterobacter species, 0.125; Klebsiella species, 2; and Pseudomonas aeruginosa, 8.
Goldstein
Ellie J C
EJ
R. M. Alden Research Laboratory, 2021 Santa Monica Blvd, #740 East, Santa Monica, CA 90404, USA. ejcgmd@aol.com
Citron
Diane M
DM
Merriam
C Vreni
CV
Warren
Yumi A
YA
Tyrrell
Kerin L
KL
Fernandez
Helen T
HT
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001420:Bacteria, Aerobic / Q000187:drug effects*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D002511:Cephalosporins / Q000494:pharmacology*; D017719:Diabetic Foot / Q000382:microbiology*; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole